Faron Pharmaceuticals Announces Oversubscribed 30 Million And Milestone Of 255 Patients Treated In Clinical Study On Bexmarilimab Cancer Medication

In Faron's first human study on bex, it treated 219 patients in advanced stages of 10 different solid tumor cancer types, including gastric, pancreatic, liver, and breast cancer, and a further 36 in hematological malignancies.